📣 VC round data is live. Check it out!
- Public Comps
- Anatolia Geneworks
Anatolia Geneworks Valuation Multiples
Discover revenue and EBITDA valuation multiples for Anatolia Geneworks and similar public comparables like Envoy Medical, Sequana Medical, Svas Biosana, K Pharma and more.
Anatolia Geneworks Overview
About Anatolia Geneworks
Anatolia Tani Ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi Ve Ticaret AS is an international biotechnology company. It is engaged in designing, developing, and manufacturing Real-Time PCR kits, nucleic acid extraction kits, and automated nucleic acid extraction instruments. It also manufactures NA Extraction kits, Microbiology kits, Genetic Disorders kits, Panel kits, Sequencing kits, Food Testing kits.
Founded
2010
HQ

Employees
N/A
Website
Financials (FY)
EV
$62M
Valuation Multiples
Start free trialAnatolia Geneworks Financials
Anatolia Geneworks reported last fiscal year revenue of $16M and negative EBITDA of ($2M).
In the same fiscal year, Anatolia Geneworks generated $10M in gross profit, ($2M) in EBITDA losses, and had net loss of ($7M).
Anatolia Geneworks P&L
In the most recent fiscal year, Anatolia Geneworks reported revenue of $16M and EBITDA of ($2M).
Anatolia Geneworks is unprofitable as of last fiscal year, with gross margin of 64%, EBITDA margin of (13%), and net margin of (42%).
Financial data powered by Morningstar, Inc.
Anatolia Geneworks Stock Performance
Anatolia Geneworks has current market cap of $55M, and enterprise value of $62M.
Market Cap Evolution
Anatolia Geneworks' stock price is $0.25.
Anatolia Geneworks share price increased by 2.4% in the last 30 days, and by 9.0% in the last year.
Anatolia Geneworks has an EPS (earnings per share) of $-0.03.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $62M | $55M | 1.5% | 2.4% | 8.4% | 9.0% | $-0.03 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialAnatolia Geneworks Valuation Multiples
Anatolia Geneworks trades at 3.9x EV/Revenue multiple, and (28.7x) EV/EBITDA.
Anatolia Geneworks Financial Valuation Multiples
As of June 3, 2026, Anatolia Geneworks has market cap of $55M and EV of $62M.
Anatolia Geneworks has a P/E ratio of (8.0x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Anatolia Geneworks Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Anatolia Geneworks Margins & Growth Rates
In the most recent fiscal year, Anatolia Geneworks reported gross margin of 64%, EBITDA margin of (13%), and net margin of (42%).
Anatolia Geneworks Margins
Anatolia Geneworks Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Anatolia Geneworks Operational KPIs
Data powered by FactSet, Inc. and Morningstar, Inc.
Anatolia Geneworks Competitors
Anatolia Geneworks competitors include Envoy Medical, Sequana Medical, Svas Biosana, K Pharma, Singular Health, Bactiguard, SciBase Holding, Nortech Systems, Daxor and HeartBeam.
Most Anatolia Geneworks public comparables operate across Laboratory Services, Medical Devices, DeepTech and HealthTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 123.8x | 133.4x | (1.4x) | - | |||
| 775.8x | 28.9x | (2.0x) | (4.0x) | |||
| 0.7x | 0.7x | 5.4x | 5.5x | |||
| - | - | (7.0x) | - | |||
| 288.8x | - | (9.6x) | - | |||
| 3.0x | 3.1x | 15.0x | 18.6x | |||
| 10.2x | 8.1x | (5.0x) | (5.5x) | |||
| 0.6x | - | 28.8x | - | |||
This data is available for Pro users. Sign up to see all Anatolia Geneworks competitors and their valuation data. Start Free Trial | ||||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Anatolia Geneworks
| When was Anatolia Geneworks founded? | Anatolia Geneworks was founded in 2010. |
| Where is Anatolia Geneworks headquartered? | Anatolia Geneworks is headquartered in Turkey. |
| Is Anatolia Geneworks publicly listed? | Yes, Anatolia Geneworks is a public company listed on Borsa Istanbul. |
| What is the stock symbol of Anatolia Geneworks? | Anatolia Geneworks trades under ANGEN ticker. |
| When did Anatolia Geneworks go public? | Anatolia Geneworks went public in 2021. |
| Who are competitors of Anatolia Geneworks? | Anatolia Geneworks main competitors include Envoy Medical, Sequana Medical, Svas Biosana, K Pharma, Singular Health, Bactiguard, SciBase Holding, Nortech Systems, Daxor, HeartBeam. |
| What is the current market cap of Anatolia Geneworks? | Anatolia Geneworks' current market cap is $55M. |
| What is the current revenue of Anatolia Geneworks? | Anatolia Geneworks' last fiscal year revenue is $16M. |
| What is the current EV/Revenue multiple of Anatolia Geneworks? | Current revenue multiple of Anatolia Geneworks is 3.9x. |
| Is Anatolia Geneworks profitable? | No, Anatolia Geneworks is not profitable. |
| How many companies Anatolia Geneworks has acquired to date? | Anatolia Geneworks hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies Anatolia Geneworks has invested to date? | Anatolia Geneworks hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to Anatolia Geneworks
Lists including Anatolia Geneworks
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.